^
BRAF V600K
Melanoma
trametinib + dabrafenib + PDR001
Sensitive: B - Late Trials
J Immunother Cancer - 4 days - (New B)
GNA11 mutation
Uveal Melanoma
binimetinib + STA-4783
Sensitive: D – Preclinical
Oncogene - 1 week - (New D)
GNAQ mutation
Uveal Melanoma
binimetinib + STA-4783
Sensitive: D – Preclinical
Oncogene - 1 week - (New D)
GNA11 mutation
Uveal Melanoma
STA-4783
Sensitive: D – Preclinical
Oncogene - 1 week - (New D)
GNAQ mutation
Uveal Melanoma
STA-4783
Sensitive: D – Preclinical
Oncogene - 1 week - (New D)
TMB-H
Melanoma
nivolumab + ipilimumab
Sensitive: A2 - Guideline
Sci Rep - 2 weeks - (New C3)
TMB-H
Melanoma
ipilimumab
Sensitive: B - Late Trials
Sci Rep - 2 weeks - (New C3)
TMB-H
Melanoma
nivolumab
Sensitive: B - Late Trials
Sci Rep - 2 weeks - (New C3)
TMB-H
Melanoma
pembrolizumab
Sensitive: B - Late Trials
Sci Rep - 2 weeks - (New C3)
TMB-H
Melanoma
pembrolizumab + ipilimumab
Sensitive: C3 – Early Trials
Sci Rep - 2 weeks - (New C3)
BRAF mutation
Melanoma
PD1 inhibitor + STAT3 inhibitor
Sensitive: D – Preclinical
Mol Ther Oncolytics - 2 weeks - (New D)
BRAF V600E
Melanoma
trametinib + dabrafenib
Sensitive: A1 - Approval
Curr Probl Cancer - 3 weeks - (New C4)
BRAF V600
Melanoma
trametinib + dabrafenib
Sensitive: A1 - Approval
J Clin Oncol - 3 weeks - (New C3)
BRAF V600K
Melanoma
pembrolizumab + trametinib + dabrafenib
Sensitive: C2 – Inclusion Criteria
J Clin Oncol - 3 weeks - (New C3)
BRAF V600E
Melanoma
pembrolizumab + trametinib + dabrafenib
Sensitive: C2 – Inclusion Criteria
J Clin Oncol - 3 weeks - (New C3)
BRAF V600
Melanoma
pembrolizumab + trametinib + dabrafenib
Sensitive: C2 – Inclusion Criteria
J Clin Oncol - 3 weeks - (New C3)
TP53 wild-type
Melanoma
trametinib + dabrafenib + KRT-232
Sensitive: C3 – Early Trials
Invest New Drugs - 3 weeks - (New C3)
NRAS mutation
Melanoma
temozolomide + rivoceranib
Sensitive: C3 – Early Trials
Melanoma Res - 3 weeks - (New C3)
KIT mutation
Melanoma
temozolomide + rivoceranib
Sensitive: C3 – Early Trials
Melanoma Res - 3 weeks - (New C3)
BRAF mutation
Melanoma
temozolomide + rivoceranib
Sensitive: C3 – Early Trials
Melanoma Res - 3 weeks - (New C3)
BRAF V600
Melanoma
vemurafenib + atezolizumab + cobimetinib
Sensitive: A1 - Approval
BRAF V600E
Melanoma
dabrafenib
Sensitive: A1 - Approval
BRAF V600
Melanoma
encorafenib + binimetinib
Sensitive: A1 - Approval
BRAF V600K
Melanoma
trametinib + dabrafenib
Sensitive: A1 - Approval
No biomarker
Melanoma
pembrolizumab
Sensitive: A1 - Approval
BRAF V600E
Melanoma
vemurafenib + cobimetinib
Sensitive: A1 - Approval
BRAF V600
Melanoma
vemurafenib + cobimetinib
Sensitive: A1 - Approval
BRAF V600E
Melanoma
vemurafenib
Sensitive: A1 - Approval
BRAF V600E
Melanoma
trametinib
Sensitive: A1 - Approval
No biomarker
Melanoma
nivolumab
Sensitive: A1 - Approval
No biomarker
Melanoma
ipilimumab
Sensitive: A1 - Approval
No biomarker
Melanoma
nivolumab + ipilimumab
Sensitive: A1 - Approval
PD-L1 underexpression
Melanoma
ipilimumab
Sensitive: A1 - Approval
PD-L1 underexpression
Melanoma
nivolumab + ipilimumab
Sensitive: A1 - Approval
BRAF V600
Melanoma
dabrafenib
Sensitive: A1 - Approval
No biomarker
Melanoma
trametinib
Resistant: A1 - Approval
BRAF V600
Melanoma
trametinib
Sensitive: A1 - Approval
BRAF V600K
Melanoma
trametinib
Sensitive: A1 - Approval
BRAF V600
Melanoma
vemurafenib
Sensitive: A1 - Approval
No biomarker
Cutaneous Melanoma
ipilimumab
Sensitive: A1 - Approval
BRAF V600K
Melanoma
encorafenib + binimetinib
Sensitive: A1 - Approval
BRAF V600E
Melanoma
encorafenib + binimetinib
Sensitive: A1 - Approval
BRAF V600K
Melanoma
vemurafenib + cobimetinib
Sensitive: A1 - Approval
LDH elevation
Melanoma
nivolumab + ipilimumab
Sensitive: A1 - Approval
No biomarker
Melanoma
aldesleukin
Sensitive: A1 - Approval
No biomarker
Melanoma
nivolumab / relatlimab
Sensitive: A1 - Approval
HLA-A*02:01
Uveal Melanoma
tebentafusp
Sensitive: A1 - Approval
No biomarker
Melanoma
BNT111
Sensitive: A1 - Approval
BRAF V600 wild-type
Melanoma
nivolumab + ipilimumab
Sensitive: A1 - Approval
BRAF V600
Melanoma
pembrolizumab
Sensitive: A1 - Approval
No biomarker
Cutaneous Melanoma
TC
Sensitive: A2 - Guideline
No biomarker
Uveal Melanoma
TC
Sensitive: A2 - Guideline
No biomarker
Uveal Melanoma
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Uveal Melanoma
nivolumab
Sensitive: A2 - Guideline
No biomarker
Uveal Melanoma
ipilimumab
Sensitive: A2 - Guideline
No biomarker
Uveal Melanoma
dacarbazine
Sensitive: A2 - Guideline
No biomarker
Uveal Melanoma
temozolomide
Sensitive: A2 - Guideline
BRAF V600
Cutaneous Melanoma
trametinib
Resistant: A2 - Guideline
BRAF V600
Cutaneous Melanoma
vemurafenib + atezolizumab + cobimetinib
Sensitive: A2 - Guideline
No biomarker
Cutaneous Melanoma
paclitaxel
Sensitive: A2 - Guideline
No biomarker
Cutaneous Melanoma
albumin-bound paclitaxel
Sensitive: A2 - Guideline
No biomarker
Cutaneous Melanoma
temozolomide
Sensitive: A2 - Guideline
No biomarker
Cutaneous Melanoma
dacarbazine
Sensitive: A2 - Guideline
No biomarker
Cutaneous Melanoma
nivolumab + ipilimumab
Sensitive: A2 - Guideline
No biomarker
Uveal Melanoma
trametinib
Sensitive: A2 - Guideline
No biomarker
Uveal Melanoma
paclitaxel
Sensitive: A2 - Guideline
No biomarker
Uveal Melanoma
albumin-bound paclitaxel
Sensitive: A2 - Guideline
No biomarker
Uveal Melanoma
nivolumab + ipilimumab
Sensitive: A2 - Guideline
No biomarker
Cutaneous Melanoma
pembrolizumab + ipilimumab
Sensitive: A2 - Guideline
BRAF mutation
Melanoma
dabrafenib + granisetron intravenous
Sensitive: A2 - Guideline
BRAF V600
Cutaneous Melanoma
vemurafenib + cobimetinib
Sensitive: A2 - Guideline
BRAF V600E
Cutaneous Melanoma
trametinib + dabrafenib
Sensitive: A2 - Guideline
NRAS mutation
Melanoma
binimetinib
Sensitive: A2 - Guideline
BRAF V600
Cutaneous Melanoma
encorafenib + binimetinib
Sensitive: A2 - Guideline
BRAF V600
Melanoma
BRAF inhibitor + MEK inhibitor
Sensitive: A2 - Guideline
NTRK1 fusion
Melanoma
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Melanoma
larotrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
Melanoma
larotrectinib
Sensitive: A2 - Guideline
BRAF V600
Cutaneous Melanoma
dabrafenib + SNR1611
Sensitive: A2 - Guideline
BRAF V600
Cutaneous Melanoma
nivolumab + ipilimumab
Sensitive: A2 - Guideline
BRAF V600K
Cutaneous Melanoma
trametinib + dabrafenib
Sensitive: A2 - Guideline
BRAF V600K
Cutaneous Melanoma
pembrolizumab
Sensitive: A2 - Guideline
BRAF V600E
Cutaneous Melanoma
pembrolizumab
Sensitive: A2 - Guideline
BRAF V600K
Cutaneous Melanoma
nivolumab
Sensitive: A2 - Guideline
BRAF V600E
Cutaneous Melanoma
nivolumab
Sensitive: A2 - Guideline
No biomarker
Cutaneous Melanoma
nivolumab
Sensitive: A2 - Guideline
No biomarker
Cutaneous Melanoma
pembrolizumab
Sensitive: A2 - Guideline
ROS1 fusion
Melanoma
entrectinib
Sensitive: A2 - Guideline
KIT exon 11 mutation
Melanoma
sunitinib
Sensitive: A2 - Guideline
KIT exon 11 mutation
Melanoma
nilotinib
Sensitive: A2 - Guideline
KIT exon 13 mutation
Melanoma
sunitinib
Sensitive: A2 - Guideline
BRAF V600K
Melanoma
dabrafenib
Sensitive: A2 - Guideline
ROS1 fusion
Melanoma
crizotinib
Sensitive: A2 - Guideline
NTRK3 fusion
Melanoma
entrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
Melanoma
entrectinib
Sensitive: A2 - Guideline
KIT exon 13 mutation
Melanoma
nilotinib
Sensitive: A2 - Guideline
BRAF fusion
Melanoma
sorafenib
Sensitive: A2 - Guideline
ALK fusion
Melanoma
crizotinib
Sensitive: A2 - Guideline
ALK fusion
Melanoma
entrectinib
Sensitive: A2 - Guideline
BRAF V600
Cutaneous Melanoma
pembrolizumab + dabrafenib
Sensitive: A2 - Guideline
No biomarker
Cutaneous Melanoma
talimogene laherparepvec
Sensitive: A2 - Guideline
No biomarker
Cutaneous Melanoma
CaT
Sensitive: A2 - Guideline
No biomarker
Cutaneous Melanoma
paclitaxel + albumin-bound paclitaxel + dacarbazine
Sensitive: A2 - Guideline
No biomarker
Cutaneous Melanoma
CVD
Sensitive: A2 - Guideline
BRAF V600E
Cutaneous Melanoma
encorafenib + binimetinib
Sensitive: A2 - Guideline
BRAF V600K
Cutaneous Melanoma
encorafenib + binimetinib
Sensitive: A2 - Guideline
BRAF V600E
Cutaneous Melanoma
vemurafenib + cobimetinib
Sensitive: A2 - Guideline
BRAF V600E
Cutaneous Melanoma
dabrafenib
Sensitive: A2 - Guideline
BRAF V600E
Cutaneous Melanoma
vemurafenib
Sensitive: A2 - Guideline
BRAF V600
Cutaneous Melanoma
pembrolizumab + trametinib
Sensitive: A2 - Guideline
No biomarker
Cutaneous Melanoma
PD1 inhibitor + talimogene laherparepvec
Resistant: A2 - Guideline
No biomarker
Cutaneous Melanoma
ipilimumab + talimogene laherparepvec
Sensitive: A2 - Guideline